

Supplementary Table 3. Treatment duration, modification, and exposure

Dose Level Dosage Days on/days off	Weekly	Biweekly	Biweekly	Monthly	Weekly	Biweekly	Monthly	Weekly	Biweekly	Monthly	Weekly	Overall (n = 69)
	DL 1	DL 2	DL 3A	DL 3B	DL 3C	DL 4A	DL 4B	DL 4C	DL 5A	DL 5B	DL 5C	
	15 mg 3 d/4 d (n = 7)	15 mg 3 d/11 d (n = 7)	25 mg 3 d/11 d (n = 4)	30 mg 4 d/24 d (n = 6)	15 mg 2 d/5 d (n = 6)	40 mg 3 d/11 d (n = 7)	45 mg 4 d/24 d (n = 7)	25 mg 2 d/5 d (n = 7)	30 mg 3 d/11 d (n = 6)	55 mg 4 d/24 d (n = 6)	35 mg 2 d/5 d (n = 6)	
Median (range) overall duration, wk Cycles, n (%)	6.7 (2, 18)	8.3 (2, 64)	35.3 (8, 64)	8.1 (8, 9)	6.5 (1, 62)	14.0 (8, 36)	8.0 (4, 44)	7.0 (2, 19)	8.0 (4, 25)	8.8 (4, 32)	7.5 (2, 13)	8.0 (1, 64)
1	1 (14.3)	2 (28.6)	0	0	2 (33.3)	0	2 (28.6)	2 (28.6)	1 (16.7)	1 (16.7)	2 (33.3)	13 (18.8)
2	4 (57.1)	2 (28.6)	2 (50.0)	6 (100)	2 (33.3)	2 (28.6)	2 (28.6)	2 (28.6)	4 (66.7)	2 (33.3)	2 (33.3)	30 (43.5)
3	1 (14.3)	0	0	0	0	1 (14.3)	0	0	0	2 (33.3)	2 (33.3)	6 (8.7)
4	0	2 (28.6)	0	0	0	2 (28.6)	1 (14.3)	1 (14.3)	0	0	0	6 (8.7)
5	1 (14.3)	0	0	0	0	0	0	0	0	0	0	3 (4.3)
6	0	0	0	0	0	0	0	0	1 (16.7)	0	0	1 (1.4)
7-12	0	0	0	0	1 (16.7)	2 (28.6)	2 (28.6)	0	0	1 (16.7)	0	6 (8.7)
13-18	0	1 (14.3)	2 (50.0)	0	1 (16.7)	0	0	0	0	0	0	4 (5.8)
Median (range) RDI, %	94.3 (72.7, 100)	93.8 (72.4, 100)	100 (73.5, 100)	99.1 (88.9, 100)	100 (99.2, 100)	95.4 (50.0, 100)	100 (77.8-119.1)	81.3 (64.7, 100)	99.1 (93.3, 107.7)	98.9 (76.4, 127.3)	93.8 (46.2, 100)	100 (46.2, 127.3)
≥1 reduction, n (%)	0	0	1 (25.0)	0	0	3 (42.9)	0	2 (28.6)	0	1 (16.7)	2 (33.3)	9 (13.0)
Due to AEs	0	0	1 (25.0)	0	0	3 (42.9)	0	2 (28.6)	0	0	1 (16.7)	8 (11.6)
≥1 interruption, n (%)	6 (85.7)	6 (85.7)	2 (50.0)	2 (33.3)	5 (83.3)	4 (57.1)	1 (14.3)	6 (85.7)	3 (50.0)	3 (50.0)	4 (66.7)	42 (60.9)

AE, adverse event; DL, dose level; RDI, relative dose intensity.